Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1161 | 1085 | 1267 | 1393 | 1707 | 2212 |
Fund Return | 16.1% | 8.49% | 26.74% | 11.69% | 11.29% | 8.26% |
Place in category | 19 | 123 | 12 | 25 | 101 | 57 |
% in Category | 1 | 6 | 1 | 2 | 6 | 4 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPMorgan Global Income D div EUR | 16.84B | 1.85 | -1.95 | 1.43 | ||
JPM Global Income A acc EUR | 16.84B | 2.00 | -1.60 | 1.78 | ||
JPMorgan Global Income A Div EUR | 16.84B | 2.00 | -1.60 | 1.78 | ||
LU0740858492 | 16.84B | 1.85 | -1.95 | 1.42 | ||
JPM Global Income Fund A Mth EUR | 16.84B | 2.00 | -1.61 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund E Acc EUR | 20.84M | 8.03 | 4.29 | 4.35 | ||
European Growth Fund Y Acc EUR | 135.29M | 8.71 | 5.97 | 6.00 | ||
European Growth Fund A DIST Eue | 6.29B | 8.40 | 5.09 | 5.14 | ||
European Growth Fund Y DIST EUR | 62.62M | 8.72 | 5.97 | 6.00 | ||
European Growth Fund A Acc EUR | 173.77M | 8.37 | 5.07 | 5.13 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
JPMorgan Liquidity Funds Euro Liquidity Fund X ( | LU0836346931 | 8.14 | 10,378.690 | +0.01% | |
Novo Nordisk B | DK0062498333 | 4.53 | 1,005.6 | +0.30% | |
ASML Holding | NL0010273215 | 3.86 | 964.20 | +0.44% | |
Novartis | CH0012005267 | 2.79 | 96.17 | +0.75% | |
Nestle | CH0038863350 | 2.43 | 91.72 | -0.46% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Strong Buy | Buy |
Technical Indicators | Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review